PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
1 clinical trials · Condition
◉ Watch PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
| Record | Firm | Date |
|---|---|---|
| Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) (NCT03094832) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2017-05-16 |
Track PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome automatically
Every clearance here is in the API, with alerts when new ones post.